Disease relevance of Aminomux

• The breast cancer and myeloma study demonstrated noninferiority of Zol compared with Pam, with Zol retaining at least 49.3% of the Pam treatment effect previously demonstrated in placebo-controlled trials [1].
• There were no differences in tolerability between zoledronic acid and pamidronic acid in comparative trials; the most common events in pivotal trials were fever, anaemia, nausea, constipation and dyspnoea [2].
• Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma [3].
• With the higher dose of amidronate the distribution could be, however, monitored only for 7 days because of the toxicity of the drug [4].
• PTH or pamidronate prevented the deleterious effects of protein undernutrition and even significantly improved the implant osseointegration [5].

High impact information on Aminomux

• Pamidronic acid is beneficial in improving BMD in CF patients before and after transplantation [6].
• FACS analysis in NCI-H295 cells treated with either CLO or PAM demonstrated both apoptotic and necrotic cell death [7].
• Furthermore, bisphosphonates are expensive (up to 775 US dollars per month, 2002 value) and cost-effectiveness evaluations have been limited to pamidronate (pamidronic acid) [8].
• Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis [9].
• X-rays, magnetic resonance (MRI) scan, whole body scintigraphy, single photon emission computer tomography (SPECT) and 3D-reconstruction from bone SPECT was performed to evaluate clinical improvement after treatment with sandostatin and pamidronic acid [10].

Chemical compound and disease context of Aminomux

• Furthermore, in patients with breast cancer and osteolytic lesions, median time to a first SRE was more than 4 months longer with zoledronic acid than with pamidronic acid [11].

Anatomical context of Aminomux

• This agrees with the suggestion that amidronate, but not the other two, can interfere with the mononuclear phagocyte system of spleen and liver [4].

Associations of Aminomux with other chemical compounds

• The decrease of urinary hydroxyproline follows an exponential curve, with a calculated half-life of 2.2 days, suggesting an approximate equivalency of 5 mg/day ABDP to slightly more than 30 mg/day 3-amino-1-hydroxypropylidene-1,1-diphosphonate [12].

References